Published in Curr Biol on June 29, 2000
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med (2004) 4.41
BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med (2000) 3.43
Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol (2010) 3.30
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood (2003) 2.82
Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci U S A (2004) 2.57
Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood (2005) 2.37
Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum (2012) 2.21
APRIL modulates B and T cell immunity. J Clin Invest (2002) 2.07
B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol (2001) 1.82
Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev (2011) 1.70
Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep (2001) 1.66
Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol Rev (2012) 1.60
Dominant-negative effect of the heterozygous C104R TACI mutation in common variable immunodeficiency (CVID). J Clin Invest (2007) 1.58
Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J Exp Med (2001) 1.57
The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol (2012) 1.49
Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol (2006) 1.43
APRIL-deficient mice have normal immune system development. Mol Cell Biol (2004) 1.29
Differential requirement of MALT1 for BAFF-induced outcomes in B cell subsets. J Exp Med (2009) 1.13
APRIL and BAFF connect autoimmunity and cancer. J Exp Med (2000) 1.11
Selective activation of TACI by syndecan-2. Blood (2005) 1.09
Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord (2010) 1.08
The C104R mutant impairs the function of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) through haploinsufficiency. J Allergy Clin Immunol (2010) 1.08
B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. Blood (2005) 1.06
Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjögren's syndrome. Arthritis Res Ther (2011) 1.01
Actions of BAFF in B cell maturation and its effects on the development of autoimmune disease. Ann Rheum Dis (2003) 1.00
Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis (2004) 0.98
Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther (2008) 0.95
Regulatory roles of the tumor necrosis factor receptor BCMA. Crit Rev Immunol (2012) 0.94
Future prospects in biologic therapy for systemic lupus erythematosus. Nat Rev Rheumatol (2013) 0.93
Homeostatic control of B lymphocyte subsets. Immunol Res (2008) 0.92
Natural antisense RNA inhibits the expression of BCMA, a tumour necrosis factor receptor homologue. BMC Mol Biol (2002) 0.92
Update on Targets of Biologic Therapies for Rheumatoid Arthritis. Curr Rheumatol Rev (2008) 0.89
A pathway switch directs BAFF signaling to distinct NFκB transcription factors in maturing and proliferating B cells. Cell Rep (2014) 0.89
Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival. PLoS One (2011) 0.88
CD28-B7 interaction modulates short- and long-lived plasma cell function. J Immunol (2012) 0.88
The TNF family member APRIL promotes colorectal tumorigenesis. Cell Death Differ (2012) 0.88
The design and characterization of receptor-selective APRIL variants. J Biol Chem (2012) 0.86
Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma. Am J Hematol (2009) 0.86
New roles for the BLyS/BAFF family in antigen-experienced B cell niches. Cytokine Growth Factor Rev (2014) 0.86
SLE--systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res Ther (2003) 0.86
B-cell-activating factor inhibits CD20-mediated and B-cell receptor-mediated apoptosis in human B cells. Immunology (2008) 0.85
T lymphocyte dependence of the antibody response to 'T lymphocyte independent type 2' antigens. Immunology (2004) 0.84
Increased serum APRIL differentially correlates with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients. Rheumatol Int (2014) 0.83
Genome-wide scan identifies variant in TNFSF13 associated with serum IgM in a healthy Chinese male population. PLoS One (2012) 0.83
MyD88 is involved in myeloid as well as lymphoid hematopoiesis independent of the presence of a pathogen. Am J Blood Res (2013) 0.83
TACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice. Oral Dis (2011) 0.82
Development of Novel Immunotherapies for Multiple Myeloma. Int J Mol Sci (2016) 0.82
Role of Tumor Necrosis Factor Superfamily in Neuroinflammation and Autoimmunity. Front Immunol (2015) 0.81
APRIL mediates peritoneal B-1 cell homeostasis. Immunol Lett (2014) 0.80
Association Study of a Proliferation-inducing Ligand, Spermatogenesis Associated 8, Platelet-derived Growth Factor Receptor-alpha, and POLB Polymorphisms with Systemic Lupus Erythematosus in Chinese Han Population. Chin Med J (Engl) (2016) 0.78
Factors regulating immunoglobulin production by normal and disease-associated plasma cells. Biomolecules (2015) 0.78
Functional expression of a proliferation-related ligand in hepatocellular carcinoma and its implications for neovascularization. World J Gastroenterol (2005) 0.78
B-cell homeostasis requires complementary CD22 and BLyS/BR3 survival signals. Int Immunol (2010) 0.78
Increased susceptibility of cord blood B lymphocytes to undergo spontaneous apoptosis. Clin Exp Immunol (2006) 0.76
Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy. Medicine (Baltimore) (2016) 0.76
Glial cell activation, recruitment, and survival of B-lineage cells following MCMV brain infection. J Neuroinflammation (2016) 0.76
Heterozygosity for transmembrane activator and calcium modulator ligand interactor A144E causes haploinsufficiency and pneumococcal susceptibility in mice. J Allergy Clin Immunol (2016) 0.75
Tumor necrosis factor superfamily member APRIL contributes to fibrotic scar formation after spinal cord injury. J Neuroinflammation (2016) 0.75
B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases. Dig Dis Sci (2016) 0.75
APRIL gene polymorphism and serum sAPRIL levels in children with systemic lupus erythematosus. Clin Rheumatol (2016) 0.75
Intracellular B Lymphocyte Signalling and the Regulation of Humoral Immunity and Autoimmunity. Clin Rev Allergy Immunol (2017) 0.75
Death receptors: signaling and modulation. Science (1998) 16.95
Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A (1996) 12.89
FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex. Cell (1996) 12.07
FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell (1995) 9.81
Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell (1995) 9.22
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem (1998) 8.30
Caspases: intracellular signaling by proteolysis. Cell (1997) 7.46
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (1997) 6.82
TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science (1995) 6.41
The receptor for the cytotoxic ligand TRAIL. Science (1997) 6.39
IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science (1997) 6.30
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem (1996) 6.22
Apoptosis signaling. Annu Rev Biochem (2000) 6.18
An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science (1997) 6.10
Apoptosis control by death and decoy receptors. Curr Opin Cell Biol (1999) 4.54
Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell (2000) 4.19
An induced proximity model for caspase-8 activation. J Biol Chem (1998) 4.18
Molecular ordering of the cell death pathway. Bcl-2 and Bcl-xL function upstream of the CED-3-like apoptotic proteases. J Biol Chem (1996) 3.97
Caspase activation: the induced-proximity model. Proc Natl Acad Sci U S A (1999) 3.86
Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J Biol Chem (1995) 3.83
FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem (1996) 3.72
Keratinocytes as initiators of inflammation. Lancet (1991) 3.68
Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ (2003) 3.66
Thrombospondin binds falciparum malaria parasitized erythrocytes and may mediate cytoadherence. Nature (1985) 3.53
Interaction of CED-4 with CED-3 and CED-9: a molecular framework for cell death. Science (1997) 3.51
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity (2000) 3.45
Target protease specificity of the viral serpin CrmA. Analysis of five caspases. J Biol Chem (1997) 3.41
The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J Biol Chem (1990) 3.41
Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. J Biol Chem (1992) 3.36
Sex differences in brain gray and white matter in healthy young adults: correlations with cognitive performance. J Neurosci (1999) 3.21
Caspase-9 can be activated without proteolytic processing. J Biol Chem (1999) 3.20
Primary structure and biochemical properties of an M2 muscarinic receptor. Science (1987) 3.16
A linear-time algorithm for computing inversion distance between signed permutations with an experimental study. J Comput Biol (2001) 3.15
A novel RING finger protein interacts with the cytoplasmic domain of CD40. J Biol Chem (1994) 3.13
The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem (1992) 3.13
Crystal structure of recombinant farnesyl diphosphate synthase at 2.6-A resolution. Biochemistry (1994) 3.10
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature (1998) 2.98
The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem (1992) 2.90
RAIDD is a new 'death' adaptor molecule. Nature (1997) 2.89
Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science (1995) 2.88
Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science (1996) 2.87
Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol (2001) 2.85
Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol (2000) 2.78
Role of CED-4 in the activation of CED-3. Nature (1997) 2.76
Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol (2001) 2.75
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med (2001) 2.66
RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase. J Biol Chem (1998) 2.58
The domains of death: evolution of the apoptosis machinery. Trends Biochem Sci (1999) 2.56
New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene (2010) 2.56
A new implementation and detailed study of breakpoint analysis. Pac Symp Biocomput (2001) 2.49
Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell (1999) 2.42
Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem (2001) 2.40
Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J (1987) 2.39
Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. J Biol Chem (1997) 2.33
A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol (1997) 2.31
Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex. J Biol Chem (1998) 2.25
Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol (1991) 2.24
ICE-LAP3, a novel mammalian homologue of the Caenorhabditis elegans cell death protein Ced-3 is activated during Fas- and tumor necrosis factor-induced apoptosis. J Biol Chem (1996) 2.20
The cell-death machine. Curr Biol (1996) 2.18
RIP3, a novel apoptosis-inducing kinase. J Biol Chem (1999) 2.15
ICE-LAP6, a novel member of the ICE/Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B. J Biol Chem (1996) 2.12
Cleavage of automodified poly(ADP-ribose) polymerase during apoptosis. Evidence for involvement of caspase-7. J Biol Chem (1999) 2.09
A role for FADD in T cell activation and development. Immunity (1998) 2.09
Upregulation of 78-kDa glucose-regulated protein in macrophages in peripheral joints of active ankylosing spondylitis. Scand J Rheumatol (2008) 2.06
Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis. J Biol Chem (1995) 2.05
A monoclonal antibody against human thrombospondin inhibits platelet aggregation. Proc Natl Acad Sci U S A (1985) 2.04
Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. Nature (1988) 2.03
FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens. J Biol Chem (1997) 2.01
ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol (2000) 2.01
Apoptotic molecular machinery: vastly increased complexity in vertebrates revealed by genome comparisons. Science (2001) 1.97
Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet (1999) 1.96
ICEBERG: a novel inhibitor of interleukin-1beta generation. Cell (2000) 1.95
Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors. Science (2000) 1.95
New paradigm for lymphocyte granule-mediated cytotoxicity. Target cells bind and internalize granzyme B, but an endosomolytic agent is necessary for cytosolic delivery and subsequent apoptosis. J Biol Chem (1996) 1.94
Isolation and characterization of a heparin-binding domain from the amino terminus of platelet thrombospondin. J Biol Chem (1984) 1.94
Cell surface thrombospondin is functionally essential for vascular smooth muscle cell proliferation. J Cell Biol (1988) 1.94
An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science (1998) 1.93
TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol (2001) 1.92
Lymphoid expression and regulation of A20, an inhibitor of programmed cell death. J Immunol (1995) 1.91
Ligand-induced autoregulation of IFN-gamma receptor beta chain expression in T helper cell subsets. Science (1995) 1.90
The platelet glycoprotein thrombospondin binds specifically to sulfated glycolipids. J Biol Chem (1985) 1.90
A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis. J Biol Chem (1997) 1.88
Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene (1995) 1.87
I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J Biol Chem (1997) 1.86
The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. J Biol Chem (1996) 1.84
Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res (2000) 1.81
The MHC-binding and gp120-binding functions of CD4 are separable. Science (1989) 1.77
Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett (1998) 1.75
Serologic association between human papillomavirus type 16 infection and esophageal cancer in Shaanxi Province, China. J Natl Cancer Inst (1996) 1.75
The baculovirus p35 protein inhibits Fas- and tumor necrosis factor-induced apoptosis. J Biol Chem (1995) 1.72
Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. Curr Biol (1996) 1.72
Monoclonal antibodies that recognize calcium-dependent structures of human thrombospondin. Characterization and mapping of their epitopes. J Biol Chem (1986) 1.69